Tower Research Capital (TRC)’s LakeShore Biopharma LSB Stock Holding History

Tower Research Capital (TRC)’s Portfolio LSB Stock Details LSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-280	Closed	-$686	–	5634
2025 Q1	$686	Buy	+280	New	+$693	﹤0.01%	4845
2024 Q1	–	Hold	0	–	-$2	–	6206
2023 Q4	–	Sell	-22	Closed	-$127	–	5885
2023 Q3	$177	Buy	+22	New	+$254	﹤0.01%	5670

Other funds holding LSB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

SCM

Superstring Capital Management New York $140M AUM 323.19% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Tower Research Capital (TRC)'s LSB Position: Q2 2025 in Review

Tower Research Capital (TRC) sold out of LakeShore Biopharma (LSB) in Q2 2025, closing a stake of 280 shares — an estimated $686 sold.

Tower Research Capital (TRC) first reported a position in LSB in Q3 2023 and held it in 2 quarters. The position peaked at $686 in Q1 2025. 7 funds tracked by Wall St. Rank hold LSB as of Q2 2025.

Tower Research Capital (TRC) reported no remaining LakeShore Biopharma position as of Q2 2025 after selling out during the quarter.
Tower Research Capital (TRC) sold 280 LakeShore Biopharma shares in Q2 2025, an estimated $686.
Tower Research Capital (TRC) first reported a position in LakeShore Biopharma in Q3 2023 and held it in 2 quarters.
Tower Research Capital (TRC)'s LakeShore Biopharma position peaked at $686 in Q1 2025.
7 funds tracked by Wall St. Rank held LakeShore Biopharma as of Q2 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2025, filed 15 Aug 2025.